Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase.

American journal of hematology - 1 Dec 2008

Weinreb Neal, Taylor John, Cox Timothy, Yee John, vom Dahl Stephan

Abstract excerpt

To assess the extent to which patients with type 1 Gaucher disease (GD1) receiving individualized enzyme replacement therapy with imiglucerase attain six defined therapeutic goals. One hundred and ninety-five GD1 patients enrolled in the ICGG Gaucher Registry, all of whom had data available for hemoglobin, platelet count, liver volume, spleen volume, bone pain, and bone crises at first infusion and after 4 years...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Child
Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gaucher Disease

Share to Glucosylceramidase

Share to Longitudinal Studies

Share to Recombinant Proteins

Share to Registries

Share to Young Adult

Source

Identifiers

PMID: 18819093
DOI: 10.1002/ajh.21280

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase.PMID 18819093Read ↗

Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.Semantic proximity Read ↗

The Importance of a Multidisciplinary Approach in the Management of a Patient with Type I Gaucher DiseaseSemantic proximity Read ↗

Gaucher disease: recommendations on diagnosis, evaluation, and monitoring.Semantic proximity Read ↗

[Therapeutic objectives in Gaucher disease].Semantic proximity Read ↗

Therapeutic goals in Gaucher disease.Semantic proximity Read ↗

Baseline characteristics of 32 patients with Gaucher disease who were treated with imiglucerase: South African data from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.Semantic proximity Read ↗

Demographics and patient characteristics of 1209 patients with Gaucher disease: Descriptive analysis from the Gaucher Outcome Survey (GOS).Semantic proximity Read ↗

An Overview of Gaucher DiseaseSemantic proximity Read ↗

A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease.Semantic proximity Read ↗

Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease.Semantic proximity Read ↗

How I treat Gaucher disease.Semantic proximity Read ↗

The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.